Effects of smoking status and MADRS retardation factor on response to low frequency repetitive transcranial magnetic stimulation for depression

Poulet, Emmanuel; Galvão, Filipe; Haffen, Emmanuel; Szekely, David; Brault, Coralie; Haesebaert, Frédéric

doi:10.1016/j.eurpsy.2016.04.004

Cited by 8 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early prediction of trajectory of response is of main interest to avoid false hope in patients and to decrease the financial and time burden associated with rTMS treatment in patients with MDE. Some clinical (e.g., retardation, smoking status [4]) and biological measures such as neurophysiological features (e.g., cortical excitability measures), genetic polymorphisms (e.g., BDNF or COMT) and imaging measures (with either EEG, PET, SPECT or fMRI) have been proposed as predictive markers of response to rTMS [5]. However, their large-scale use in clinical settings is limited by their usefulness at an individual level as well as their costs and accessibility.…”

Section: Dear Editormentioning

confidence: 99%

Predicting treatment response to 1Hz rTMS using early self-rated clinical changes in major depression

et al. 2020

View full text Add to dashboard Cite

Section: Dear Editormentioning

confidence: 99%

Predicting treatment response to 1Hz rTMS using early self-rated clinical changes in major depression

et al. 2020

View full text Add to dashboard Cite

“…Other analyses may support certain conclusions-although still highly debated in the literature-on the basis of the 3-factor model of the MADRS, mainly used to assess clinical features of (non)responders to neurostimulation treatments. 73,74 The "dysphoria" factor 1 (including reported sadness, pessimistic thoughts, and suicidal thoughts) and the "retardation" factor 2 (including apparent sadness, concentration difficulties, lassitude, and inability to feel) showed notable improvement from the first week (−26.7% and −20%, respectively; P < 0.001), with the most positive changes in reported sadness, apparent sadness, and lassitude.…”

Section: Discussionmentioning

confidence: 99%

Dynamics of Depressive and Psychomotor Symptoms During Electroconvulsive Therapy in Older Depressive Patients

Droguene¹,

Bulteau

Deschamps

et al. 2023

J ECT

View full text Add to dashboard Cite

ObjectiveElectroconvulsive therapy (ECT) is an effective treatment for patients experiencing a major depressive episode, especially older ones. Identification of specific responses within early ECT sessions remains an issue of debate, however. Hence, this pilot study prospectively examined the outcome in terms of depressive signs, symptom by symptom, throughout a course of ECT, concentrating particularly on psychomotor retardation symptoms.MethodsNine patients were clinically evaluated several times during the ECT course, before the first session and then weekly (over 3–6 weeks, according to their evolution), by completing the Montgomery-Åsberg Depression Rating Scale (MADRS), the Mini-Mental State Examination test, and the French Retardation Rating Scale for Depression for assessing the severity of psychomotor retardation.ResultsNonparametric Friedman tests showed significant positive changes in mood disorders during ECT in older depressive patients (mean, −27.3% of initial MADRS total score). Fast improvement in French Retardation Rating Scale for Depression score was observed at t1 (ie, after 3–4 ECT sessions), whereas a slightly delayed improvement in the MADRS scores was found at t2 (ie, after 5–6 ECT sessions). Moreover, the scores for items linked to the motor component of psychomotor retardation (eg, gait, postural control, fatigability) were the first to significantly decrease during the first 2 weeks of the ECT course compared with the cognitive component.ConclusionsInterestingly, participants' concentration on daily functional activities, their interest and fatigability, and their reported state of sadness were the first to progress, representing possible precursor signs of positive patient outcomes after ECT.

show abstract

“…141 Moreover, greater response to a LF-rTMS protocol has been associated with lower MADRS retardation scores at baseline. 142 Regarding ECT, even first-line recommendations such as older age, psychosis, and melancholic features 21 were not consistently identified in a meta-analysis. 133 One study reported that ECT responders displayed higher scores on a MADRS dysphoria factor compared to nonresponders, while the procedure had only a small effect on a MADRS vegetative factor.…”

Section: Convulsive Modalitiesmentioning

confidence: 98%

Precision non-implantable neuromodulation therapies: a perspective for the depressed brain

Borrione

Bellini

Razza

et al. 2020

Braz. J. Psychiatry

View full text Add to dashboard Cite

Current first-line treatments for major depressive disorder (MDD) include pharmacotherapy and cognitive-behavioral therapy. However, one-third of depressed patients do not achieve remission after multiple medication trials, and psychotherapy can be costly and time-consuming. Although nonimplantable neuromodulation (NIN) techniques such as transcranial magnetic stimulation, transcranial direct current stimulation, electroconvulsive therapy, and magnetic seizure therapy are gaining momentum for treating MDD, the efficacy of non-convulsive techniques is still modest, whereas use of convulsive modalities is limited by their cognitive side effects. In this context, we propose that NIN techniques could benefit from a precision-oriented approach. In this review, we discuss the challenges and opportunities in implementing such a framework, focusing on enhancing NIN effects via a combination of individualized cognitive interventions, using closed-loop approaches, identifying multimodal biomarkers, using computer electric field modeling to guide targeting and quantify dosage, and using machine learning algorithms to integrate data collected at multiple biological levels and identify clinical responders. Though promising, this framework is currently limited, as previous studies have employed small samples and did not sufficiently explore pathophysiological mechanisms Brazilian Psychiatric Association 0 0 0 0 0 0 0 0 -0 0 0 2 -7 3 1 6 -1 1 8 5 associated with NIN response and side effects. Moreover, cost-effectiveness analyses have not been performed. Nevertheless, further advancements in clinical trials of NIN could shift the field toward a more ''precision-oriented'' practice. DisclosureZ-DD is listed as inventor on patents/patent applications related to brain stimulation technology, assigned to Columbia University and NEVA Electromagnetics, not licensed, and with no remuneration. Although he is an employee of the U.S. government, the views expressed Braz J Psychiatry. 2020;00 (00) Precision NIN for depression

show abstract

Effects of smoking status and MADRS retardation factor on response to low frequency repetitive transcranial magnetic stimulation for depression

Abstract: Low MADRS retardation factor and ex-smoker status is highly prevalent in responders to low frequency rTMS. Further studies are needed to investigate the predictive value of these factors.

Cited by 8 publications

References 60 publications

Predicting treatment response to 1Hz rTMS using early self-rated clinical changes in major depression

Predicting treatment response to 1Hz rTMS using early self-rated clinical changes in major depression

Dynamics of Depressive and Psychomotor Symptoms During Electroconvulsive Therapy in Older Depressive Patients

Precision non-implantable neuromodulation therapies: a perspective for the depressed brain

Contact Info

Product

Resources

About